NCT00304200 - Temodar and Sutent as Therapy for Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

January 31, 2009

Conditions

Metastatic Malignant Melanoma

Interventions

DRUG

Temozolomide and SU11248

First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.

Trial Locations (1)

Northern California Melanoma Center, San Francisco